INTRODUCTION
Colorectal cancer, hypertensive, CRC, hypertension
HYPERTENSION, DIFFERENTIATED THYROID CANCER, MALIGNANCIES, HEPATOCELLULAR CARCINOMA, RENAL CELL CARCINOMA, COLORECTAL CANCER, PATHOGENESIS, PREECLAMPSIA
Colorectal cancer (CRC) is the second most common cause of cancer‐related mortality worldwide. Over the last two decades, there have been advancements leading to an expansion of the therapeutic armentarium, leading to improved patient outcomes. Multi‐kinase anti‐angiogenic receptor tyrosine kinase inhibitors (TKIs), which represent important agents for a number of malignancies, are now also established therapeutic options for metastatic CRC. For example, regorafenib is associated with improved survival.A number of published reports have suggested that TKI‐induced hypertension represents a clinical biomarker or surrogate for benefit. Better survivals have been reported in patients with TKI‐induced hypertension compared to patients who did not develop hypertension in renal cell carcinoma, well differentiated thyroid cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma.Simultaneously, we wanted to explore any potential changes in the circulating metabolome in order to derive an improved understanding of the pathogenesis of TKI‐induced hypertension. The metabolome has been intensively investigated in hypertensive conditions such as preeclampsia.